已收盤 09-22 16:00:00 美东时间
0.000
0.00%
Frequency Electronics, Inc. (FEI) marked a milestone as Voyager 1 reached one light-day from Earth, powered by FEI's ultra-stable oscillators (USOs) developed in 1973. These USOs enabled precise radio science, studying planetary atmospheres and rings. FEI, a leader in precision timing since 1961, continues to innovate, supplying critical timing solutions for space, defense, and communications. Their commitment to stability and long life in produc...
11-19 13:30
Gain Therapeutics announced positive clinical data from a Phase 1b study of rexaceract for Parkinson's disease, showing stable MDS-UPDRS motor scores and no disease progression in 13 participants after 12 months of treatment. The study also highlighted the potential of cerebrospinal fluid (CSF) GluSph as a disease-specific biomarker, with differential responses observed between Parkinson's patients and one participant diagnosed with multiple syst...
11-17 21:15
Magellan Aerospace ( ($TSE:MAL) ) has issued an announcement. Magellan Aerospac...
11-07 07:08
Magnolia Oil & Gas (NYSE:MGY) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga...
11-06 00:42
Gain Therapeutics announced the presentation of two late-breaking posters at the 31st IAPRD World Congress on Parkinson’s Disease in Milan and one poster at Neuroscience 2026 in Washington, D.C. The posters highlight the company’s lead drug candidate, rexaceract (GT-02287), and its novel GCase allosteric modulator GT-04686, focusing on their potential in treating Parkinson’s disease and related disorders. The posters will be presented during guid...
11-05 12:00
Magellan Aerospace ( ($TSE:MAL) ) has shared an announcement. Magellan Aerospac...
10-28 05:12
Magellan Financial Group Ltd ( ($AU:MFG) ) has provided an announcement. Magell...
10-22 04:48
Gain Therapeutics, Inc. will participate in the 2026 Maxim Growth Summit from October 12-14 in New York City. The company will meet with institutional investors and engage with Maxim research analysts. Gain’s lead drug candidate, rexaceract, is in a Phase 1b trial for Parkinson’s disease and has potential for Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. The company uses its Magellan™ platform to develop novel allosteric ...
10-08 11:00
Gain Therapeutics announced a poster presentation at the International Congress of Parkinson’s Disease and Movement Disorders in Seoul, detailing long-term open-label data on its GCase modulator, Rexaceract (GT-02287), for Parkinson’s disease treatment. Rexaceract, an orally administered small molecule, targets GBA1 mutations and age-related stress, restoring GCase function and reducing neurodegenerative markers. The Phase 1 study showed favorabl...
09-29 21:50
Magellan Financial Group Ltd ( ($AU:MFG) ) just unveiled an announcement. Magel...
09-23 15:07